Functional Apolipoprotein A-I mutant proteins, having one or more cysteine substitutions and polynucleotides encoding same, can be used to modulate paraoxonase's arylesterase activity. These ApoA-I mutant proteins can be used as therapeutic agents to combat cardiovascular disease, atherosclerosis, acute phase response and other inflammatory related diseases. The invention also includes modifications and optimizations of the ApoA-I nucleotide sequence for purposes of increasing protein expression and optimization.
STATEMENT OF GOVERNMENT SUPPORT
This invention was made during work partially supported through the U.S. Department of Energy under Contract No. DE-AC03-76SF00098. The government has certain rights in this invention.